Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides — playbook

Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides

Fusion Pharmaceuticals · 2024-01

arc beats above · slides in the middle · loops below · scroll → 2 LOOPS

Deck intelligence map

5

coverage by narrative range · generated from this deck JSON

Narrative range 10 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem 3 slides 100% 3/3 slides 100% 3/3 slides · 13 hits

— 0/3 slides

66.7% 2/3 slides · 3 hits

— 0/3 slides

100% 3/3 slides

— 0/3 slides

Solution 4 slides 100% 4/4 slides 100% 4/4 slides · 20 hits

— 0/4 slides

— 0/4 slides

75% 3/4 slides 100% 4/4 slides · 5 hits

— 0/4 slides

Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 9 hits

— 0/1 slides

— 0/1 slides

— 0/1 slides

100% 1/1 slides · 2 hits

— 0/1 slides

Competition 1 slides 100% 1/1 slides 100% 1/1 slides · 9 hits

— 0/1 slides

— 0/1 slides

100% 1/1 slides 100% 1/1 slides

— 0/1 slides

Team 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits

— 0/1 slides

— 0/1 slides

— 0/1 slides

100% 1/1 slides

— 0/1 slides

Slide inventory

26

every slide · same image gating as the playbook

01

front_matter

Open slide detail

02

other

Open slide detail

03

The slide uses a four-column layout to summarize the company's value proposition.summarize

Open slide detailBeat · Problem

04

transition

Open slide detailBeat · Problem

05

The slide uses a before/after PET scan visual to demonstrate clinical efficacy.show_traction

Open slide detailBeat · Problem

06

The slide uses a process diagram to show the evolution of the FPI-2265 program.show_traction

Open slide detailBeat · Solution

07

The slide uses a process flow diagram to illustrate the transition from Phase 2 (n=60) to Phase 3 (n=550).plan_implementation

Open slide detailBeat · Solution

08

Uses a combination of clinical trial data (VISION) and market projections to justify the TAM for FPI-2265.size_opportunity

Open slide detailBeat · Solution

09

plan_implementation

Open slide detailBeat · Solution

10

transition

Open slide detail

11

The slide uses a comparative structure to highlight the superiority of alpha particles in DNA damage and clinical logistics.argue_timing

Open slide detailLoop · Cost Of Inaction

12

The slide highlights a partnership-based supply chain and a proprietary onsite generator technology to mitigate risks associated with traditional cyclotron prodpresent_solution

Open slide detail

13

Highlights internal manufacturing readiness and scale.present_solution

Open slide detail

14

transition

Open slide detail

15

The slide uses a standard pharmaceutical pipeline visualization format.plan_implementation

Open slide detail

16

The slide compares clinical trial data from two different studies (Morris et al. 2017 and Hofman et al. 2018) to illustrate the efficacy of different PSMA-targecompare_peers

Open slide detailBeat · Competition

17

Includes a visual comparison between a 'cold' antibody and the 'hot' FPI-1434 conjugate.present_solution

Open slide detailLoop · Quick Win Big Bet

18

Includes medical imaging (SPECT/CT) comparing baseline vs. cold antibody intervention.show_traction

Open slide detailLoop · Quick Win Big Bet

19

Includes before/after PET-CT scan imagery.show_traction

Open slide detailLoop · Quick Win Big Bet

20

transition

Open slide detail

21

The chart shows a clear dose-dependent reduction in tumor volume compared to vehicle and cold antibody controls.show_traction

Open slide detail

22

The slide uses a 'before-after' logic to explain the transition from 177Lu to 225Ac.present_solution

Open slide detail

23

Includes headshots, titles, key experience bullets, and a grid of company logos representing past experience.other

Open slide detailBeat · Team

24

Includes a footnote explaining the pro forma cash calculation.summarize

Open slide detail

25

summarize

Open slide detail

26

state_next_steps

Open slide detail